Current gastroenterology reports

Does Resmetirom Work Well Enough for Common Fatty Liver Disease to Be Used Widely?

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Resmetirom has received accelerated FDA approval based on its safety and efficacy in achieving metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression.

  • Resmetirom is a liver-directed thyroid hormone receptor beta agonist.
  • It is associated with improvements in liver histology for patients with MASH and significant fibrosis.
  • The MAESTRO trial provided evidence for its reasonable safety profile.
  • Noninvasive tests may be useful for selecting and monitoring patients receiving resmetirom.
  • The review discusses the real-world utility of resmetirom in treating liver disease.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Competing Interests: The authors declare no competing interests. W.D has received grant/research support from 89bio, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk; reports speaker’s fees from Gilead Sciences and Madrigal Pharmaceuticals; and reports consulting for Ipsen and Novo Nordisk. N.A. has received grant/research support from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus Pharmaceuticals; reports speaker’s fees from AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Perspectum; and reports consulting for 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, and Regeneron.
PubMed

Related papers

Mar '25
Resmetirom: the first approved treatment for fatty liver disease linked to metabolism problems
top 30% journal
cited by 17 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief